FDA’s Office of Prescription Drug Promotion (OPDP) is stepping up enforcement activity, focusing scrutiny on advertising tone, imagery, and whether promotional claims match clinical evidence. The increased correspondence rate is also being read in the context of broader FDA attention to transparency. The discussion highlights that pharmaceutical firms are being pushed to revisit promotional strategies and evidence alignment, particularly around how trials are represented and how messaging maps to approved indications and study findings. In parallel, the FDA budget proposal includes a policy agenda intended to solidify OPDP authority, which could further reshape how companies structure prescription drug marketing materials going forward.